Arcutis Lifts Full-Year Sales Guidance to $535M-$545M After 45% Q3 Revenue Jump
ARQT sits 50% above its 52-week low of $19.295.
Summary
Arcutis posted Q3 2026 revenue of $143.9 million, up 45% year over year, and raised full-year sales guidance to $535 million-$545 million. The top line is the story: ZORYVE demand is broadening across formulations after the June 2026 U.S. launch of the 0.3% cream. The blemish is profitability — EPS of $0.06 came in below estimates even as sales beat, so the quarter is a growth-over-margin print. This follows the 8-K and 10-Q filed last night showing $8.8 million of quarterly net income and $259.8 million in cash, plus the upsized $200 million at-the-market program that gives them room to keep funding the launch. Next specific item: the FDA decision on infant-use ZORYVE 0.05% is due Feb. 23, 2027.
At the time of this announcement, ARQT was trading at $29.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $19.30 to $34.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.